DCPH — Deciphera Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.21bn
- $1.94bn
- $163.36m
Brief: Deciphera Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Deciphera Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter And Full Year 2021 Financial Results
Deciphera Pharmaceuticals Inc expected to post a loss of $1.33 a share - Earnings Preview
Brief: Deciphera Pharmaceuticals Presents Results From The Intrigue Phase 3 Clinical Study At The American Society Of Clinical Oncology Plenary Series Session
Brief: Deciphera Pharmaceuticals Inc - Launch Of Qinlock® In Germany Underway Transition To Post-Approval Paid Access Program In France Expected In 1H 2022
Brief: Deciphera Announces Approval Of Qinlock In The United Kingdom For The Treatment Of Fourth-Line Gastrointestinal Stromal Tumor
U.S. STOCKS ON THE MOVE-Ambarella, BeyondSpring, OceanPal, Allbirds
U.S. STOCKS ON THE MOVE-Box, BeyondSpring, Build-A-Bear Workshop, OceanPal
U.S. STOCKS ON THE MOVE-CTI BioPharma, Aditxt, OceanPal, Ardelyx
Analysts slash PTs on Deciphera citing dour near-term outlook
U.S. RESEARCH ROUNDUP-Caribou Biosciences, Immunogen, Supernus Pharmaceuticals
U.S. STOCKS ON THE MOVE-Didi, MEI Pharma, TG Therapeutics, Cumberland Pharma
Deciphera Pharmaceuticals rises on plans to cut workforce
NASDAQ RESUMED AT 09:00 AM
Brief: Deciphera Pharmaceuticals Announces Restructuring To Prioritize Clinical Development Programs And Streamline Commercial Operations
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
U.S. STOCKS ON THE MOVE-Tesla, Bluebird Bio, Zhihu, Talkspace
Deciphera Pharma rises after Europe approves tumor drug